News Search Results
May 01, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 01, 2026, 02:30 ET Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy
plannedTOKYO, May 1, 2026 /PRNewswire/ -- Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial
More news about: Restore Vision Inc.
May 01, 2026, 01:46 ET /C O R R E C T I O N -- Amity University Rajasthan/
Rankings 2026.Amity University Rajasthan provides students with cutting-edge laboratories for languages, media studies, education, pharmacy, biotechnology, engineering, and scientific research. The university focuses on developing student potential through a blend of academic excellence and real-world
More news about: Amity University Rajasthan
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Calif., May 1, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced it will present pipeline advances
More news about: Kodiak Sciences Inc.
Apr 30, 2026, 21:15 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
$14 billion. As The Wall Street Journal observed in January 2026, "[f]or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell." At all relevant times, Defendants downplayed the likelihood and severity
More news about: Pomerantz LLP
Apr 30, 2026, 21:07 ET CMEF 2026 상하이서 폐막…글로벌 의료 혁신과 미래 트렌드 한자리에
tHIS(The Health Industry Series) ASEAN 2026: 7월 28일~30일, 말레이시아 쿠알라룸푸르 컨벤션센터홍콩 국제 바이오테크놀로지 콘퍼런스 및 전시회(BIOHK, Hong Kong International Biotechnology Conference and Exhibition): 2026: 9월 9일~12일, 홍콩 컨벤션전시센터(홍콩 생명공학협회와 공동 주최)제94회 CMEF 및 전시회: 10월 21일~24일, 수도국제전시컨벤션센터(베이징)사전
More news about: CMEF
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Apr 30, 2026, 16:30 ET Halozyme to Report First Quarter 2026 Financial and Operating Results
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Apr 30, 2026, 13:10 ET La CMEF 2026 se termine à Shanghai : une scène mondiale pour les avancées médicales et les tendances futures
de Hong Kong sur la biotechnologie (BIOHK) 2026 : 9-12 septembre, Hong Kong Convention and Exhibition Centre, co-organisé avec la Hong Kong Biotechnology Organization ;La 94e CMEF et les expositions parallèles : 21-24 octobre, Capital International Exhibition & Convention Center
More news about: CMEF
Apr 30, 2026, 13:09 ET Die CMEF 2026 geht in Shanghai zu Ende: eine globale Bühne für medizinische Durchbrüche und Zukunftstrends
Kongresszentrum von Kuala Lumpur, Malaysia;Hong Kong International Biotechnology Conference and Exhibition (BIOHK) 2026: 9.-12. September, Hongkong Convention and Exhibition Centre, gemeinsam mit der Hong Kong Biotechnology Organization organisiert;Die 94. CMEF und die begleitende
More news about: CMEF
Apr 30, 2026, 12:38 ET Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the appointment of Annalisa Jenkins, M.B.B.S.,
More news about: Northwest Biotherapeutics, Inc.
Apr 30, 2026, 12:30 ET Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the appointment of Annalisa Jenkins, M.B.B.S.,
More news about: Northwest Biotherapeutics, Inc.
Apr 30, 2026, 11:47 ET Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing
deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit madescientific.com.Media ContactLucy TaylorHead of MarketingMade Scientific,
More news about: Made Scientific, Inc.
Apr 30, 2026, 11:34 ET Colossal Biosciences Expands De-extinction Portfolio with Iconic Bluebuck
not exist before. This is precision conservation at a scale the field has never seen."For too long, antelope conservation has lacked the biotechnology infrastructure that other species take for granted," said Matt James. "The bluebuck project is changing that fundamentally. The reproductive technologies,
More news about: Colossal Biosciences Inc.
Apr 30, 2026, 11:10 ET CMEF 2026 Resmi Ditutup di Shanghai, Tampilkan Inovasi Medis Global dan Tren Industri Masa Depan
Lumpur Convention Centre, Malaysia;Hong Kong International Biotechnology Conference and Exhibition (BIOHK) 2026: 9–12 September di Hong Kong Convention and Exhibition Centre, bekerja sama dengan Hong Kong Biotechnology Organization;94th CMEF and concurrent series exhibitions:
More news about: CMEF
Apr 30, 2026, 10:38 ET El primer fármaco recombinante de toxina botulínica tipo A del mundo obtiene la autorización de comercialización en China: una revolución tecnológica impulsada por Claruvis Pharmaceutical
profesionales de la salud de todo el mundo".Acerca de Claruvis PharmaceuticalClaruvis Pharmaceutical Co., Ltd, una filial de MingMed Biotechnology, es una empresa biofarmacéutica impulsada por la innovación que se dedica a la investigación, el desarrollo, la fabricación y la comercialización
More news about: Claruvis Pharmaceutical
Apr 30, 2026, 10:17 ET CMEF2026が上海で閉幕：医療のブレークスルーと将来のトレンドのためのグローバルな舞台
Series) ASEAN 2026 ：7月28～30日、マレーシアのクアラルンプール・コンベンションセンター香港国際バイオテクノロジー会議・展示会（BIOHK）2026 ：9月9日〜12日、香港コンベンション＆エキシビションセンター、 Hong Kong Biotechnology Organizationとの共催第94回CMEFと同時開催のシリーズ展示 ：10月21～24日、Capital International Exhibition & Convention Center（北京）事前登録リンク
More news about: CMEF
Apr 30, 2026, 09:00 ET Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion
Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the U.S. Food and Drug Administration (FDA) has granted
More news about: Theradaptive
Apr 30, 2026, 09:00 ET IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 30, 2026, 09:00 ET IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt
triggered the 21% single-day stock decline."This case presents important questions about drug efficacy disclosure obligations in the biotechnology sector. When promotional statements go far beyond what clinical trial data support, investors who relied on those statements to purchase shares
More news about: SueWallSt.com
Apr 30, 2026, 08:30 ET Factor Bioscience to Showcase Engineered iMacrophages (FACT-112) Targeting Ovarian Cancer In Vivo at ISCT 2026
CAMBRIDGE, Mass., April 30, 2026 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation
More news about: Factor Bioscience
Apr 30, 2026, 08:12 ET Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board
infrastructure. As Wisconsin Governor, he was known for pioneering welfare reform and promoting economic development, particularly in the healthcare and biotechnology sectors."Vector Science & Therapeutics represents exactly the kind of innovative thinking we need to address the challenges facing modern
More news about: Vector Sciences & Therapeutics
Apr 30, 2026, 08:00 ET Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
BOSTON, April 30, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced the completion of patient enrollment in
More news about: Bambusa Therapeutics
Apr 30, 2026, 08:00 ET Halozyme Appoints Darren Snellgrove as Chief Financial Officer
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Apr 30, 2026, 08:00 ET Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio
April 30, 2026 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today provided
More news about: Stealth BioTherapeutics Inc.